TY - JOUR
T1 - Spinal Cord Atrophy in Multiple Sclerosis
T2 - A Systematic Review and Meta-Analysis
AU - Casserly, Courtney
AU - Seyman, Estelle E.
AU - Alcaide-Leon, Paula
AU - Guenette, Melanie
AU - Lyons, Carrie
AU - Sankar, Stephanie
AU - Svendrovski, Anton
AU - Baral, Stefan
AU - Oh, Jiwon
N1 - Funding Information:
Acknowledgments and Disclosure: This work was funded by an unrestricted grant (Transitional Career Development Award) held by Dr. Oh from the MS Society of Canada. Dr. Oh has received funding from the MS Society of Canada, the National MS Society, Sanofi-Genzyme, and Biogen-Idec. Dr. Oh has also received compensation for consulting or speaking engagements from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, Teva, and Roche. Dr. Casserly has received personal compensation for consulting and/or travel grants from Roche, EMD-Serono, Sanofi-Genzyme, and Novartis. She has also received travel grants from the MS Society of Canada and the American Academy of Neurology, and honoraria for Continuing Medical Education (CME) course development from the Canadian Neurological Sciences Federation (CNSF). Dr. Seyman has received funding through an unrestricted educational grant from Novartis. She has also received compensation for consulting from Biogen-Idec. Dr. Alcaide-Leon has received funding through an unrestricted educational grant from Sanofi-Genzyme. None of the other authors have any disclosures to declare. The authors would like to thank Dr. Prados Carrasco Ferran and Dr. Rohit Bakshi for contributing numerical data from their studies to be included in the meta-analysis.
Funding Information:
and Disclosure: This work was funded by an unrestricted grant (Transitional Career Development Award) held by Dr. Oh from the MS Society of Canada. Dr. Oh has received funding from the MS Society of Canada, the National MS Society, Sanofi-Genzyme, and Biogen-Idec. Dr. Oh has also received compensation for consulting or speaking engagements from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, Teva, and Roche. Dr. Casserly has received personal compensation for consulting and/or travel grants from Roche, EMD-Serono, Sanofi-Genzyme, and Novartis.?She has also received travel grants from the MS Society of Canada and the American Academy of Neurology, and honoraria for Continuing Medical Education (CME) course development from the Canadian Neurological Sciences Federation (CNSF). Dr. Seyman has received funding through an unrestricted educational grant from Novartis. She has also received compensation for consulting from Biogen-Idec. Dr. Alcaide-Leon has received funding through an unrestricted educational grant from Sanofi-Genzyme. None of the other authors have any disclosures to declare. The authors would like to thank Dr. Prados Carrasco Ferran and Dr. Rohit Bakshi for contributing numerical data from their studies to be included in the meta-analysis.
Publisher Copyright:
© 2018 by the American Society of Neuroimaging
PY - 2018/11/1
Y1 - 2018/11/1
N2 - BACKGROUND AND PURPOSE: Spinal cord atrophy (SCA) is an important emerging outcome measure in multiple sclerosis (MS); however, there is limited consensus on the magnitude and rate of atrophy. The objective of this study was to synthesize the available data on measures of SCA in MS. METHODS: Using published guidelines, relevant literature databases were searched between 1977 and 2017 for case-control or cohort studies reporting a quantitative measure of SCA in MS patients. Random-effects models pooled cross-sectional measures and longitudinal rates of SCA in MS and healthy controls (HCs). Student's t-test assessed differences between pooled measures in patient subgroups. Heterogeneity was assessed using DerSimonian and Laird's Q-test and the I 2-index. RESULTS: A total of 1,465 studies were retrieved including 94 that met inclusion and exclusion criteria. Pooled estimates of mean cervical spinal cord (SC) cross-sectional area (CSA) in all MS patients, relapsing-remitting MS (RRMS), all progressive MS, secondary progressive MS (SPMS), primary-progressive MS (PPMS), and HC were: 73.07 mm2 (95% CI [71.52-74.62]), 78.88 mm2 (95% CI [76.92-80.85]), 69.72 mm2 (95% CI [67.96-71.48]), 68.55 mm2 (95% CI [65.43-71.66]), 70.98 mm2 (95% CI [68.78-73.19]), and 80.87 mm2 (95% C I [78.70-83.04]), respectively. Pooled SC-CSA was greater in HC versus MS (P <.001) and RRMS versus progressive MS (P <.001). SCA showed moderate correlations with global disability in cross-sectional studies (r-value with disability score range [−.75 to −.22]). In longitudinal studies, the pooled annual rate of SCA was 1.78%/year (95%CI [1.28-2.27]). CONCLUSIONS: The SC is atrophied in MS. The magnitude of SCA is greater in progressive versus relapsing forms and correlates with clinical disability. The pooled estimate of annual rate of SCA is greater than reported rates of brain atrophy in MS. These results demonstrate that SCA is highly relevant as an imaging outcome in MS clinical trials.
AB - BACKGROUND AND PURPOSE: Spinal cord atrophy (SCA) is an important emerging outcome measure in multiple sclerosis (MS); however, there is limited consensus on the magnitude and rate of atrophy. The objective of this study was to synthesize the available data on measures of SCA in MS. METHODS: Using published guidelines, relevant literature databases were searched between 1977 and 2017 for case-control or cohort studies reporting a quantitative measure of SCA in MS patients. Random-effects models pooled cross-sectional measures and longitudinal rates of SCA in MS and healthy controls (HCs). Student's t-test assessed differences between pooled measures in patient subgroups. Heterogeneity was assessed using DerSimonian and Laird's Q-test and the I 2-index. RESULTS: A total of 1,465 studies were retrieved including 94 that met inclusion and exclusion criteria. Pooled estimates of mean cervical spinal cord (SC) cross-sectional area (CSA) in all MS patients, relapsing-remitting MS (RRMS), all progressive MS, secondary progressive MS (SPMS), primary-progressive MS (PPMS), and HC were: 73.07 mm2 (95% CI [71.52-74.62]), 78.88 mm2 (95% CI [76.92-80.85]), 69.72 mm2 (95% CI [67.96-71.48]), 68.55 mm2 (95% CI [65.43-71.66]), 70.98 mm2 (95% CI [68.78-73.19]), and 80.87 mm2 (95% C I [78.70-83.04]), respectively. Pooled SC-CSA was greater in HC versus MS (P <.001) and RRMS versus progressive MS (P <.001). SCA showed moderate correlations with global disability in cross-sectional studies (r-value with disability score range [−.75 to −.22]). In longitudinal studies, the pooled annual rate of SCA was 1.78%/year (95%CI [1.28-2.27]). CONCLUSIONS: The SC is atrophied in MS. The magnitude of SCA is greater in progressive versus relapsing forms and correlates with clinical disability. The pooled estimate of annual rate of SCA is greater than reported rates of brain atrophy in MS. These results demonstrate that SCA is highly relevant as an imaging outcome in MS clinical trials.
KW - Spinal cord atrophy
KW - magnetic resonance imaging (MRI)
KW - meta-analysis
KW - multiple sclerosis
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85053258530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053258530&partnerID=8YFLogxK
U2 - 10.1111/jon.12553
DO - 10.1111/jon.12553
M3 - Article
C2 - 30102003
AN - SCOPUS:85053258530
SN - 1051-2284
VL - 28
SP - 556
EP - 586
JO - Journal of Neuroimaging
JF - Journal of Neuroimaging
IS - 6
ER -